Royalty Pharma PLC (RPRX)
26.43
+0.03
(+0.11%)
USD |
NASDAQ |
Nov 22, 16:00
26.41
-0.02
(-0.08%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.74B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.23% |
| Valuation | |
| PE Ratio | 10.36 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.953 |
| Price to Book Value | 1.709 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.21 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.107 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
| URL | https://www.royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 15, 2024 |
Ratings
Profile
| Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
| URL | https://www.royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 15, 2024 |